Skip to content

Study · Randomized controlled trial · n = 9 · 1995

3 results

Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature.

Tuilpakov AN, Bulatov AA, Peterkova VA, Elizarova GP, Volevodz NN, Bowers CY

Metabolism: clinical and experimental1 Sept 1995Cited by 9 (Europe PMC)

PMID7666796 (opens in a new tab)DOI10.1016/0026-0495(95)90016-0 (opens in a new tab)PepBankPUB-07666796
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In children with GH insufficiency, the peak GH was above 5.0 micrograms/L in only one of nine cases after GHRP‑2 and in three of 10 cases after GHRH1-29NH2.

    In plain wordsIn children with GH insufficiency, GHRP‑2 produced a low growth hormone response, like GHRH1-29NH2 did.

    Peptide
    GHRP-2
    Outcome
    No significant changePeak GH above 5.0 micrograms/L after GHRP-2 (GH insufficiency)
    Study

    n = 9

    Comparator
    GHRH1-29NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Patients in group A showed low GH responses to both GHRH1-29NH2 and GHRP-2 stimulation: in only three of 10 and one of nine cases, respectively, were the peak GH levels above 5.0 micrograms/L.
    2 context sentences
    Summary · context
    Ten children with GHI (aged 11.8 +/- 1.1 years; height, -4.2 +/- 0.5 SDS) and five children with ISS (aged 11.1 +/- 1.2 years; height, -3.2 +/- 0.1 SDS) were studied.
    Summary · context
    Intravenous bolus infusions of GHRH1-29NH2 (1 micrograms/kg), GHRP-2(1 microgram/kg), and GHRH plus GHRP-2 (each 1 micrograms/kg), were administered in a randomized order.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In children with idiopathic short stature, GH responses to GHRP‑2 and GHRH1-29NH2 were of about the same magnitude (P = .9).

    In plain wordsIn children with idiopathic short stature, GHRP‑2 and GHRH1-29NH2 gave about the same growth hormone response.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH AUC after GHRP-2 versus GHRH (idiopathic short stature)
    Study

    n = 5

    Comparator
    GHRH1-29NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    In group B, GH responses to GHRH1-29NH2 and GHRP-2 were approximately of the same magnitude (1,943 +/- 819 v 1,981 +/- 887 micrograms/L.min, P = .9).(ABSTRACT TRUNCATED AT 250 WORDS)
    2 context sentences
    Summary · context
    Ten children with GHI (aged 11.8 +/- 1.1 years; height, -4.2 +/- 0.5 SDS) and five children with ISS (aged 11.1 +/- 1.2 years; height, -3.2 +/- 0.1 SDS) were studied.
    Summary · context
    Intravenous bolus infusions of GHRH1-29NH2 (1 micrograms/kg), GHRP-2(1 microgram/kg), and GHRH plus GHRP-2 (each 1 micrograms/kg), were administered in a randomized order.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In children with GH insufficiency, GH AUC at 90 minutes after GHRP‑2 was slightly less than after GHRH1-29NH2 (179 versus 214 micrograms/L.min, P = .06).

    In plain wordsIn children with GH insufficiency, GHRP‑2 gave a slightly smaller growth hormone response than GHRH1-29NH2, not clearly different.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH AUC (90 min) after GHRP-2 versus GHRH (GH insufficiency)
    Study

    n: not reported in source

    Comparator
    GHRH1-29NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Measurements

    GH AUC
    179 micrograms/L.min
    GHRP-2, group A
    GH AUC
    214 micrograms/L.min
    GHRH1-29NH2, group A

    Source sentences

    Summary
    GH area under the curve (AUC) 90 minutes after GHRP-2 administration was slightly less than for GHRH1-29NH2 (179 +/- 150 v 214 +/- 68 micrograms/L.min, P = .06).
    2 context sentences
    Summary · context
    Ten children with GHI (aged 11.8 +/- 1.1 years; height, -4.2 +/- 0.5 SDS) and five children with ISS (aged 11.1 +/- 1.2 years; height, -3.2 +/- 0.1 SDS) were studied.
    Summary · context
    Intravenous bolus infusions of GHRH1-29NH2 (1 micrograms/kg), GHRP-2(1 microgram/kg), and GHRH plus GHRP-2 (each 1 micrograms/kg), were administered in a randomized order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.